Is a complete VNDA research report available?

No complete published report is available for Vanda Pharmaceuticals Inc. (VNDA) on this page. Market-directory data, when present, is not a substitute for a reviewed stock analysis.

Vanda Pharmaceuticals Inc. (VNDA)

NASDAQ: VNDA · USD

$5.05

-0.11 (-2.1%)· Recorded snapshot

Coverage state: Market snapshot only — no published research

Market snapshot recorded 2026-07-30 02:00 UTC. No published research is attached to this ticker. Prices and fundamentals on this server-rendered page are dated snapshots, not a real-time trading feed.

On-demand research

Generate the first VNDA analysis

Start the full research workflow when this ticker is ready in our data system.

Market cap	303.7M
Revenue (ttm)	217.8M
Net income (ttm)	-239.5M
EPS (ttm)	-$4.05
Shares out	60.1M
Volume	781,643
Beta	0.60
Price target	$14.1	+179.8%

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 217.8M
Net income (ttm): -239.5M
EPS (ttm): -$4.05
Market cap: 303.7M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
ALNY	Alnylam Pharmaceuticals, Inc.	27.4B	36.9x	5.7x	96.6%	+47.5%	-37.8%	Strong Buy
ARGX	argenx SE	53.8B	31.3x	10.1x	50.6%	+58.8%	+45.7%	Strong Buy
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Hold

All VNDA indicators

Market & fundamental data

Available fields

225

Groups with data

Currency

USD

Showing 225 of 225 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001347178
Company name	Vanda Pharmaceuticals Inc.
Country	United States
Country code	US
Cusip	921659108
Employees	533
Employees Change	165%
Employees Change Percent	44.84
Enterprise value	$114.4M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2006-04-12
Isin	US9216591084
Last refreshed	2026-07-30
Market cap	$303.7M
Market cap category	Small-Cap
Price	$5.05
Price currency	USD
Rev Per Employee	408,596.62x
Sector	Healthcare
Sector PE	45.64
Sector PE Fwd	24.21
Sic	2834
Symbol	VNDA
Website	https://www.vandapharma.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-78.88%
EV Sales Forward	0.39x
EV/Sales	0.53x
FCF yield	-41.92%
P/B ratio	1.08x
P/S ratio	1.39x
PS Forward	1.04x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	-73.64%
EBITDA Margin	-69.78%
Gross margin	94.18%
Gross Profit	$205.1M
Gross Profit Growth	7.97%
Gross Profit Growth Q	4.38%
Gross Profit Growth3 Y	-4.2%
Gross Profit Growth5 Y	-2.15%
Net Income	$-239.5M
Net Income Growth Years	0%
Pretax Margin	-68.74%
Profit Margin	-109.99%
Profit Per Employee	$-449,432
ROA	-18.81
Roa5y	-3.29
ROCE	-53.82
ROE	-60.48
Roe5y	-9.16
ROIC	-191.5
Roic5y	-21.57

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	-7.9%
Cagr15y	-2.39%
Cagr1y	7.45%
Cagr20y	-2.98%
Cagr3y	-5.27%
Cagr5y	-23.7%
EPS Growth Years	0
Revenue Growth	8.16x
Revenue Growth Q	3.35x
Revenue Growth Quarters	8x
Revenue Growth Years	2x
Revenue Growth3 Y	-5.33x
Revenue Growth5 Y	-2.94x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.41
Assets	$433.5M
Cash	$202.3M
Current Assets	$293.2M
Current Liabilities	$135.6M
Debt	$13.1M
Debt Equity	$0.05
Equity	$280.8M
Liabilities	$152.8M
Long Term Assets	$140.4M
Long Term Liabilities	$17.2M
Net Cash	$189.2M
Net Cash By Market Cap	$62.31
Net Cash Growth	-42.51%
Net Debt Equity	$-0.67
Tangible Book Value	$165.7M
Tangible Book Value Per Share	$2.75
WACC	7.25

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	2.16
Inventory Turnover	7
Net Working Capital	$-38.7M
Quick ratio	1.91
Working Capital	$157.6M
Working Capital Turnover	$0.94

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-1.41%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	-56.09%
1Y total return	7.45%
200-day SMA	6.53
3Y total return	-14.98%
50-day SMA	5.95
50-day SMA vs 200-day SMA	50under200
5Y total return	-74.14%
All Time High	33.44
All Time High Change	-84.9%
All Time High Date	2018-12-03
All Time Low	0.45
All Time Low Change	1,022.22%
All Time Low Date	2008-12-23
ATR	0.23
Beta	0.6
Beta1y	0.52
Beta2y	0.68
Ch YTD	-42.74
High	5.19
High52	9.94
High52 Date	2026-03-10
High52ch	-49.2%
Low	4.94
Low52	4.14
Low52 Date	2025-08-07
Low52ch	21.98%
Ma50ch	-15.13%
Premarket Change Percent	0
Premarket Price	$5.16
Price vs 200-day SMA	-22.62%
RSI	29.74
RSI Monthly	45.16
RSI Weekly	39.33
Sharpe ratio	0.42x
Sortino ratio	0.8
Total Return	-1.41%
Tr YTD	-42.74
Tr15y	-30.44%
Tr1m	-15.97%
Tr1w	-5.61%
Tr3m	-26.17%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	4
Analyst Count Top	3
Analyst Price Target Top	$18.67
Analyst Ratings	Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$-0.57
Earnings Revenue Estimate	62,070,000x
Earnings Revenue Estimate Growth	18.03x
Operating Income	$-160.4M
Operating margin	-73.64
Price target	$14.13
Price Target Change	$180
Price Target Change Top	$270

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	53,838,664%
Float Percent	89.53%
Net Borrowing	-2,358,000
Shares Insiders	4.22%
Shares Institutions	72.95%
Shares Out	60,135,562
Shares Qo Q	0.61%
Shares Yo Y	1.41%
Short Float	13.35%
Short Ratio	8
Short Shares	11.95

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-136.4M
Adjusted OCF	-135,579,000
Average Volume	831,296.6x
Bv Per Share	4.67
CAPEX	$-783,000
Ch10y	-56.09
Ch15y	-30.44
Ch1m	-15.97
Ch1w	-5.61
Ch1y	7.45
Ch20y	-45.41
Ch3m	-26.17
Ch3y	-14.98
Ch5y	-74.14
Ch6m	-34.33
Change	-2.13%
Change From Open	-1.56
Close	5.16
Days Gap	-0.58
Depreciation Amortization	8,387,000
Dollar Volume	3,947,297.2
Earnings Date	2026-08-05
Earnings Time	amc
EBIT	$-160.4M
EBITDA	$-152M
EPS	$-4.05
F Score	2
FCF	$-127.3M
FCF EV Yield	-111.23x
FCF Per Share	$-2.12
Financing CF	-2,358,000
Fiscal Year End	December
Founded	2,002
Income Tax	$89.8M
Investing CF	71,192,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-06
Last Report Date	2026-03-31
Last Split Type	Never
Last10k Filing Date	2026-02-12
Ma150	6.94
Ma150ch	-27.23%
Ma20	5.74
Ma20ch	-12.01%
Net CF	-57,762,000
Next Earnings Date	2026-08-05
Open	5.13
Optionable	Yes
Position In Range	45.1
Post Close	5.05
Postmarket Change Percent	-1.98
Postmarket Price	$4.95
Ppne	14,065,000
Pre Close	5.16
Price Date	2026-07-29
Ptbv Ratio	1.83
Relative Volume	0.94x
Revenue	217,782,000x
SBC By Revenue	4.16x
Share Based Comp	9,066,000
Tax By Revenue	41.25x
Tr20y	-45.41%
Tr6m	-34.33%
Us State	District of Columbia
Volume	781,643
Z Score	-0.43

Vanda Pharmaceuticals Inc. (VNDA)

Coverage state: Market snapshot only — no published research

Generate the first VNDA analysis

Price

Financial snapshot

Fair-value bridge

Analyst consensus

Latest news · VNDA

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All VNDA indicators

Profile and market data

Valuation

Profitability

Growth

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Analyst estimates

Ownership and float

Other indicators

Deeper analysis on VNDA

Frequently asked questions